Nitinotes Advances EndoZip With First Orlando Health Procedures
CAESAREA, Israel, July 28, 2026 Nitinotes Ltd. has completed the first study procedures at Orlando Health in its pivotal...
FDA IDE
Advertisement
SpinaFX Earns CE Mark for Triojection Spine System
TORONTO, July 16, 2026 SpinaFX Medical Inc. has achieved a significant regulatory milestone with the Medical Device Regulation (MDR)...
Laplace Gains FDA IDE for TRIUMPH TTVR Pivotal Trial
MINNEAPOLIS, Minn., June 29, 2026 Laplace Interventional has reached a significant regulatory milestone after receiving U.S. Food and Drug...
Matter Bio Wins FDA IND Clearance for LM-LLO-TT Trial
SAN FRANCISCO, June 10, 2026 Matter Bio has announced that the U.S. Food and Drug Administration (FDA) has cleared...
SpinaFX Wins FDA IDE for Triojection Lumbar Disc Therapy
TORONTO, June 9, 2026 SpinaFX Medical has achieved a major regulatory milestone after receiving U.S. Food and Drug Administration...
Advertisements
Glucotrack Announces FDA IDE Submission for Implantable Continuous Blood Glucose Monitoring Technology
RUTHERFORD, N.J., May 7, 2026 Glucotrack, Inc. announced the submission of an Investigational Device Exemption (IDE) application to the...
MMI Launches REMIND Trial Using Symani System
JACKSONVILLE, FL, May 04, 2026 Medical Microinstruments (MMI) has successfully treated the first patient in its FDA-approved REMIND clinical...
Glucotrack Targets FDA IDE for CBGM Trial in 2026
RUTHERFORD, N.J., March 27, 2026 GlucoTrack announced plans to submit an Investigational Device Exemption (IDE) application to the U.S....
Myra Vision Treats First Patient in U.S. ADAPT Glaucoma Study
CAMPBELL, CALIFORNIA | January 26, 2026 — Myra Vision, a Shifamed portfolio company, announced that the first patient has...
FDA Approves U.S. Trial for EndoArt Synthetic Corneal Implant
NES ZIONA, Israel, December 8, 2025 — EyeYon Medical Ltd. announced that the U.S. Food and Drug Administration (FDA)...
Advertisement
